Conduction slowing in diabetic sensorimotor polyneuropathy

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3684-3690

  Dunnigan, Samantha K ^a   Ebadi, Hamid ^a   Breiner, Ari ^a   Katzberg, Hans D ^a   Lovblom, Leif E ^b   Perkins, Bruce A ^b   Bril, Vera ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CLINICAL EXAMINATION; COHORT ANALYSIS; DIABETIC NEUROPATHY; DIABETIC SENSORIMOTOR POLYNEUROPATHY; DISEASE SEVERITY; ELECTRODIAGNOSIS; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVE CONDUCTION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; SENSORIMOTOR NEUROPATHY; SENSORY NERVE CONDUCTION; AGED; COMPLICATION; DIABETIC NEUROPATHIES; GLUCOSE BLOOD LEVEL; HEART RATE; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; POLYNEUROPATHIES;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; POLYNEUROPATHIES;

EID: 84891865699     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0746     Document Type: Article

References (24)

1. Dyck PJ, Albers JW, Andersen H, et al.; on behalf of the Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011; 27:620-628
2. England JD, Gronseth GS, Franklin G, et al.; American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of ElectrodiagnosticMedicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64: 199-207
3. Dyck PJ, Lais A, Karnes JL, O'Brien PC, Rizza R. Fiber loss is primary andmultifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986;19:425-439
4. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977;40:1072-1082
5. Herrmann DN, Ferguson ML, Logigian EL. Conduction slowing in diabetic distal polyneuropathy. Muscle Nerve 2002;26: 232-237
6. Van den Bergh PYK, Hadden RDM, Bouche P, et al.; European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 2010; 17:356-363
7. Latov N. Biomarkers of CIDP in patients with diabetes or CMT1. J Peripher Nerv Syst 2011;16(Suppl. 1):14-17
8. Berger AR, Bradley WG, Brannagan TH, et al.; Neuropathy Association, Medical Advisory Committee. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2003;8:282-284
9. Magda P, Latov N, Brannagan TH 3rd, Weimer LH, Chin RL, Sander HW. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2003;60:1755-1759
10. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002;25:2048-2052
11. Bolton CF, Benstead TJ, Grand'Maison F, Tardif GS,Weston LE. Minimumstandards for electromyography in Canada: a statement of the Canadian Society of Clinical Neurophysiologists. Can J Neurol Sci 2000; 27:288-291
12. American Association of Electrodiagnostic Medicine. Guidelines in electrodiagnostic medicine. Recommended policy for electrodiagnostic medicine. Muscle Nerve 1999; (Suppl. 8):S91-S105
13. Wilson JR, Stittsworth JD Jr, Kadir A, Fisher MA. Conduction velocity versus amplitude analysis: evidence for demyelination in diabetic neuropathy. Muscle Nerve 1998;21:1228-1230
14. Tankisi H, Pugdahl K, Johnsen B, Fuglsang-Frederiksen A. Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies. Clin Neurophysiol 2007;118:2383-2392
15. Young RJ, Ewing DJ, Clarke BF. Nerve function and metabolic control in teenage diabetics. Diabetes 1983;32:142-147
16. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617-618
17. Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology 2003;60(Suppl. 3):S8-S15
18. Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009;277:1-8
19. Skog O, Korsgren S, Melhus A, Korsgren O. Revisiting the notion of type 1 diabetes being a T-cell-mediated autoimmune disease. Curr Opin Endocrinol Diabetes Obes 2013;20:118-123
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
21. Albers JW, Herman WH, Pop-Busui R, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090-1096
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
23. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year followup of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
24. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl. 2):B21-B29